0001104659-24-033457.txt : 20240312 0001104659-24-033457.hdr.sgml : 20240312 20240312160205 ACCESSION NUMBER: 0001104659-24-033457 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240311 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 24742003 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 tm248501d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2024

Inhibrx, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39452	82-4257312
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11025 N. Torrey Pines Road, Suite 200

La Jolla, CA 92037

(Address of principal executive offices, including zip code)

(858) 795-4220

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	INBX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

As previously disclosed, governmental and regulatory approvals are required to complete the transactions contemplated by the Agreement and Plan of Merger, dated January 22, 2024, by and among Inhibrx, Inc., a Delaware corporation (the “Company”), Aventis Inc., a Pennsylvania corporation (“Parent”) and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Merger Agreement”). These approvals include the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The Company and Sanofi each filed a Notification and Report Form pursuant to the HSR Act with respect to the Merger Agreement with the U.S. Federal Trade Commission and the U.S. Department of Justice on February 9, 2024, and the applicable 30-day statutory waiting period under the HSR Act expired at 11:59 p.m., Eastern time, on March 11, 2024. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the Merger Agreement, which remains subject to other customary closing conditions, including receipt of stockholder approval.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements about Parent’s proposed acquisition of Company and INBRX-101, and the Company’s related spin-off of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109, its existing pipeline and corporate infrastructure, which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company’s stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the integration of the Company and Sanofi will be more difficult, time consuming or costly than expected; risks and costs relating to the separation of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109 and the consummation of the spin-off in the anticipated timeframe or at all; changes to the configuration of the INBRX-105, INBRX-106 and INBRX-109 businesses included in the separation if implemented; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting management’s attention from the Company’s ongoing business operation; negative effects of this announcement or the consummation of the proposed transaction on the market price of the Company’s shares of common stock and/or operating results; significant transaction costs; risks associated with the discovery of unknown liabilities prior to or after the closing of the proposed transactions; the risk of litigation and/or regulatory actions related to the proposed transactions or the Company’s business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; the conflicts in the Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; and future business combinations or disposals. Important factors, risks and uncertainties that could cause actual results to differ materially from such forward looking statements also include but are not limited to the initiation, timing, progress and results of the Company’s research and development programs as well as the Company’s preclinical studies and clinical trials; the Company’s ability to advance therapeutic candidates into, and successfully complete, clinical trials; the Company’s interpretation of initial, interim or preliminary data from the Company’s clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals, including whether any product candidate, receives approval from the FDA, or similar regulatory authority, for an accelerated approval process; the commercialization of the Company’s therapeutic candidates, if approved; the pricing, coverage and reimbursement of the Company’s therapeutic candidates, if approved; the Company’s ability to utilize the Company’s technology platform to generate and advance additional therapeutic candidates; the implementation of the Company’s business model and strategic plans for the Company’s business and therapeutic candidates; the Company’s ability to successfully manufacture the Company’s therapeutic candidates for clinical trials and commercial use, if approved; the Company’s ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company’s therapeutic candidates; the Company’s ability to enter into strategic partnerships and the potential benefits of such partnerships; the Company’s estimates regarding expenses, capital requirements and needs for additional financing; the ability to raise funds needed to satisfy the Company’s capital requirements, which may depend on financial, economic and market conditions and other factors, over which the Company may have no or limited control; the Company’s financial performance; the Company’s and the Company’s third party partners’ and service providers’ ability to continue operations and advance the Company’s therapeutic candidates through clinical trials and the ability of the Company’s third party manufacturers to provide the required raw materials, antibodies and other biologics for the Company’s preclinical research and clinical trials in light of current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events; the ability to retain the continued service of the Company’s key professionals and to identify, hire and retain additional qualified professionals; and developments relating to the Company’s competitors and the Company’s industry; and other risks described from time to time in the “Risk Factors” section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K as well as its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Additional Information and Where to Find It

This communication is being made in connection with the proposed transaction involving the Company, Parent and the other parties to the Merger Agreement. The Company has filed a preliminary proxy statement and certain other documents, and may file additional relevant materials, regarding the proposed transaction with the SEC. The Company filed the preliminary proxy statement with the SEC on February 29, 2024. The definitive proxy statement will be mailed to the Company’s stockholders in connection with the proposed acquisition. This communication is not a substitute for the proxy statement or any other document that may be filed by the Company with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Any vote in respect of resolutions to be proposed at the Company’s annual meeting of stockholders to approve the proposed acquisition or other responses in relation to the proposed acquisition should be made only on the basis of the information contained in the Company’s proxy statement. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov or on the Company’s website at https://www.inhibrx.com.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Participants in Solicitation

The Company, its respective directors and certain of their respective executive officers may be deemed to be “participants” (as defined under Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from stockholders of the Company with respect to the potential transaction. Information about the identity of Company’s (i) directors is set forth in the section entitled “Our Board of Directors” on page 153 of Company’s Annual Report on Form 10-K filed with the SEC on February 28, 2024 (the “2024 10-K”) (and available here) and (ii) executive officers is set forth in the section entitled “Our Executive Officers” on page 157 of the 2024 10-K (and available here). Information about the compensation of Company’s non-employee directors is set forth in the section entitled “Non-Employee Director Compensation Policy” starting on page 158 of the 2024 10-K (and available here). Information about the compensation of Company’s named executive officers is set forth in the section entitled “Executive Compensation” starting on page 158 of the 2024 10-K (and available here). Transactions with related persons (as defined in Item 404 of Regulation S-K promulgated under the Securities Act of 1933) are disclosed in the section entitled “Certain Relationships and Related Party Transactions” on page 171 of the 2024 10-K (and available here). Information about the beneficial ownership of Company securities by Company’s directors and named executive officers is set forth in the section entitled “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” starting on page 167 of the 2024 10-K (and available here).

2

Any change of the holdings of the Company’s securities by its directors or executive officers from the amounts set forth in the 2024 10-K have been reflected in the following Statements of Beneficial Ownership on Form 4 filed with the SEC: Form 4, filed by Kelly Deck, with the filing of the Company on March 6, 2024. As of March 12, 2024, the “participant” set forth above “beneficially owned” (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934) less than 1% of shares of common stock, par value $0.0001 share, of the Company.

Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be included in the definitive proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov and the Company’s website at https://www.inhibrx.com.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 12, 2024

	INHIBRX, INC.

	By:	/s/ Kelly Deck
		Kelly Deck
		Chief Financial Officer

[SIGNATURE PAGE TO FORM 8-K]

EX-101.SCH 2 inhibrx-20240311.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 inhibrx-20240311_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 inhibrx-20240311_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 11, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 11, 2024
Entity File Number	001-39452
Entity Registrant Name	Inhibrx, Inc.
Entity Central Index Key	0001739614
Entity Tax Identification Number	82-4257312
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11025 N. Torrey Pines Road
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	858
Local Phone Number	795-4220
Written Communications	false
Soliciting Material	true
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	INBX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inhibrx.namespace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports inhibrx-20240311.xsd inhibrx-20240311_lab.xml inhibrx-20240311_pre.xml tm248501d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm248501d1_8k.htm": { "nsprefix": "inhibrx", "nsuri": "http://inhibrx.namespace.com/20240311", "dts": { "schema": { "local": [ "inhibrx-20240311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inhibrx-20240311_lab.xml" ] }, "presentationLink": { "local": [ "inhibrx-20240311_pre.xml" ] }, "inline": { "local": [ "tm248501d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://inhibrx.namespace.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248501d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248501d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-24-033457-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-033457-xbrl.zip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tm248501d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001739614 2024-03-11 2024-03-11 iso4217:USD shares iso4217:USD shares false 0001739614 8-K 2024-03-11 Inhibrx, Inc. DE 001-39452 82-4257312 11025 N. Torrey Pines Road Suite 200 La Jolla CA 92037 858 795-4220 false true false false Common Stock, par value $0.0001 per share INBX NASDAQ false